{"schema_version":"1","generated_at":"2026-11-21T19:54:32.343Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mukul-gupta","json_url":"https://www.findmykol.com/kol/mukul-gupta/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mukul-gupta","name":"Mukul Gupta","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Sansum Medical Clinic","institution_url":"https://www.findmykol.com/institution/sansum-medical-clinic","city":"Santa Barbara","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Mukul Gupta is an Oncology physician affiliated with Sansum Medical Clinic. OpenAlex indexes 7 publications with 3,054 citations (h-index 4).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":7,"cited_by_count":3054,"h_index":4,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":26,"program_years":{"first":2021,"last":null},"rows_total":91,"shown":3,"withheld":88,"rows":[{"payer":"Novartis","program_year":2025,"amount_usd":356676.37,"payment_count":2},{"payer":"BioNTech SE","program_year":2025,"amount_usd":93336,"payment_count":34},{"payer":"Regeneron","program_year":2025,"amount_usd":41900,"payment_count":13}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":39.2,"classes_total":3,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":24.3,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":33},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":14.7,"drugs":[{"name":"Darbepoetin alfa","share_pct":100}],"max_beneficiaries":31}]},{"area":"Cancer & immunology","share_pct":34.5,"classes_total":14,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":26.9,"drugs":[{"name":"Nivolumab","share_pct":61.7},{"name":"Pembrolizumab","share_pct":38.3}],"max_beneficiaries":19},{"class":"Platinum-based Drug","setting":"administered","share_pct":6.4,"drugs":[{"name":"Oxaliplatin","share_pct":96.5},{"name":"Carboplatin","share_pct":3.5}],"max_beneficiaries":16}]},{"area":"Metabolism & gastrointestinal","share_pct":11.8,"classes_total":7,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":9.7,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":44},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":1.9,"drugs":[{"name":"Palonosetron hcl","share_pct":52.7},{"name":"Granisetron hydrochloride","share_pct":45.9},{"name":"Ondansetron Odt","share_pct":1.1},{"name":"Ondansetron Hcl","share_pct":0.4}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.8,"facility_pct":0.2},"source":"medicare"},"publications":{"total":7,"shown":5,"withheld":2,"matched_by":"OpenAlex author record","recent":[{"title":"T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer","year":2022,"journal":"Future Oncology","source_url":"https://doi.org/10.2217/fon-2021-1134","status":"verified"},{"title":"Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma","year":2022,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.am2022-ct122","status":"verified"},{"title":"A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM).","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19522","status":"verified"},{"title":"Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. The Phase 2 KEYNOTE-180 Study","year":2019,"journal":"UCL Discovery (University College London)","status":"verified"},{"title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","year":2018,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(18)30351-6","status":"verified"}],"source":"works"},"similar":[{"name":"Andrew Mester","slug":"andrew-mester","institution":"Sansum Medical Clinic","specialty":"Otolaryngology","url":"https://www.findmykol.com/kol/andrew-mester","json_url":"https://www.findmykol.com/kol/andrew-mester/profile.json"},{"name":"Gregory Cogert","slug":"gregory-cogert","institution":"Sansum Medical Clinic","specialty":"Clinical Cardiac Electrophysiology","url":"https://www.findmykol.com/kol/gregory-cogert","json_url":"https://www.findmykol.com/kol/gregory-cogert/profile.json"},{"name":"Julie Taguchi","slug":"julie-taguchi","institution":"Sansum Medical Clinic","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/julie-taguchi","json_url":"https://www.findmykol.com/kol/julie-taguchi/profile.json"},{"name":"Scott Tobis","slug":"scott-tobis","institution":"Sansum Medical Clinic","specialty":"Urology","url":"https://www.findmykol.com/kol/scott-tobis","json_url":"https://www.findmykol.com/kol/scott-tobis/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":88,"publications":2}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}